
What We’re Reading: Maternal Mortality Rates; FDA Rejects Lilly's Eczema Drug; Some Abortion Ban Restrictions Lifted
A new grant aims to address maternal mortality in predominantly Black rural areas; Eli Lilly's drug to treat atopic dermatitis has not received FDA approval; a preliminary injunction is granted to Planned Parenthood South Atlantic.
Targeting High Maternal Mortality Rates in Majority-Black Rural Communities
A federal program under the Health Resources and Services Administration has awarded its first grant to an organization serving predominantly Black rural communities in the Deep South to combat high maternal mortality rates,
FDA Rejects Lilly’s Eczema Drug Due to Manufacturing Issues
The FDA has declined to approve Eli Lilly's drug lebrikizumab, intended for treating atopic dermatitis,
Federal Judge Lifts Restrictions Within North Carolina’s Abortion Ban
District Judge Catherine Eagles has lifted some restrictions in North Carolina's abortion ban, granting a preliminary injunction to Planned Parenthood South Atlantic,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.